Clinical Trials
42 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
OvAR-Y
Washington University School of Medicine
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
SHERLOCK
University Health Network, Toronto
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
iCaRe2
University of Nebraska
COPD Care Pathway Among Patients With Cancer
Wake Forest University Health Sciences
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
CHEMOVES
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
ELEPHAS-02
Elephas
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PANDA-VAC
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
LIBRETTO-001
Eli Lilly and Company
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
RAMPART
Montefiore Medical Center
A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery
Montefiore Medical Center
TraveraRTGx
Travera Inc
GALENOS 2
Fondazione del Piemonte per l'Oncologia
GALENOS 1
Fondazione del Piemonte per l'Oncologia
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Abramson Cancer Center at Penn Medicine
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
ALTAK
Centre Oscar Lambret
ALTAKRA-1405
Centre Oscar Lambret
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
MOMENTUM
UMC Utrecht
AcceleRET-Lung
Hoffmann-La Roche
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine